Inflammatory Myofibroblastic TumorSymptoms, Doctors, Treatments, Advances & More
Learn About Inflammatory Myofibroblastic Tumor
Condition 101 content is not available at this time, but we are continually updating the site. Please check back.
However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.
Patrick Schoffski practices practicing medicine in Leuven, Belgium. Mr. Schoffski is rated as an Elite expert by MediFind in the treatment of Inflammatory Myofibroblastic Tumor. He is also highly rated in 19 other conditions, according to our data. His clinical expertise encompasses Gastrointestinal Stromal Tumor, Adult Soft Tissue Sarcoma, Liposarcoma, Synovial Sarcoma, and Tissue Biopsy.
Raf Sciot practices practicing medicine in Leuven, Belgium. Sciot is rated as an Elite expert by MediFind in the treatment of Inflammatory Myofibroblastic Tumor. They are also highly rated in 21 other conditions, according to our data. Their clinical expertise encompasses Inflammatory Myofibroblastic Tumor, Adult Soft Tissue Sarcoma, Gastrointestinal Stromal Tumor, Thrombectomy, and Fasciotomy.
Reading Hospital Hematology Oncology
Frank Song is a Hematologist and an Oncologist practicing medicine in Phoenixville, Pennsylvania. Dr. Song is rated as an Advanced provider by MediFind in the treatment of Inflammatory Myofibroblastic Tumor. He is also highly rated in 75 other conditions, according to our data. His clinical expertise encompasses Lung Cancer, Stomach Cancer, Small Cell Lung Cancer (SCLC), Endoscopy, and Sacral Nerve Stimulation. Dr. Song is board certified in American Board Of Internal Medicine.
Summary: This is an open-label, phase I-II dose-escalation and expansion study designed to define the recommended dose of brigatinib as monotherapy in pediatric and young adult patients with ALK+ ALCL, IMT or other solid tumors and to evaluate the pharmacokinetics (PK), (long-term) safety, and efficacy of brigatinib in these children.
Summary: Phase 1 will evaluate the safety and tolerability at different dose levels of repotrectinib in pediatric and young adult subjects with advanced or metastatic malignancies harboring anaplastic lymphoma kinase (ALK), receptor tyrosine kinase encoded by the gene ROS1 (ROS1), or neurotrophic receptor kinase genes encoding TRK kinase family (NTRK1-3) alterations to estimate the Maximum Tolerated Dose (...